Inhibition of gastric inhibitory polypeptide signaling prevents obesity
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Secretion of gastric inhibitory polypeptide (GIP), a duodenal hormone, is primarily induced by absorption of ingested fat. Here we describe a novel pathway of obesity promotion via GIP. Wild-type mice fed a high-fat diet exhibited both hypersecretion of GIP and extreme visceral and subcutaneous fat deposition with insulin resistance. In contrast, mice lacking the GIP receptor (Gipr(-/-)) fed a high-fat diet were clearly protected from both the obesity and the insulin resistance. Moreover, double-homozygous mice (Gipr(-/-), Lep(ob)/Lep(ob)) generated by crossbreeding Gipr(-/-) and obese ob/ob (Lep(ob)/Lep(ob)) mice gained less weight and had lower adiposity than Lep(ob)/Lep(ob) mice. The Gipr(-/-) mice had a lower respiratory quotient and used fat as the preferred energy substrate, and were thus resistant to obesity. Therefore, GIP directly links overnutrition to obesity and it is a potential target for anti-obesity drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“tirzepatide proved superior in improving glycemic control relative to treatment with semaglutide (1 mg)133, insulin degludec134, insulin glargine135,136, and insulin lispro137; importantly, with preserved efficacy and without compromising safety in subjects at risk for cardiovascular diseases136.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Combined, the SURPASS and SURMOUNT trials have verified the safety of tirzepatide to be consistent with GLP-1R agonists, along with its enhanced efficacy at maximal doses of 5, 10 and 15 mg (Table 1)132-136,143,145-147”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“While GIPR antagonism has been shown to reduce adiposity in preclinical models [64], the clinical data show tirzepatide, a dual GLP-1R/GIPR agonist, produces greater weight loss and glucose lowering than the GLP-1R agonist semaglutide alone [42], particularly at doses which comparably engage the GLP-1R [61].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
In the citing paper
“Initial reports that GIPR null mice [64] are protected from diet-induced obesity have been supported by preclinical studies in rodents and non-human primates that GIPR antagonism induces additive weight loss when combined with GLP-1R agonism [32,67], and human genetics data that loss-of-function GIPR variants associate with reduced adiposity [68].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419 · cited 1×
“Obese Lep ob / Lep ob mice exhibit a marked increase in adipose tissue due to hyperphagia caused by mutation of the leptin gen”
BackgroundSerum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Weight-Reducing Effects of the Plasma Protein Encoded by the obese Gene
Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Burley, S. K., & Friedman, J. M. (1995) · Science · doi:10.1126/science.7624777 · Cited by 4,451
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,225
Obesity and the regulation of energy balance
Spiegelman, B. M., & Flier, J. S. (2001) · Cell · doi:10.1016/s0092-8674(01)00240-9 · Cited by 2,398
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Green, H., & Kehinde, O. (1975) · Cell · doi:10.1016/0092-8674(75)90087-2 · Cited by 1,360
Dietary fat intake does affect obesity!
Bray, G. A., & Popkin, B. M. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.6.1157 · Cited by 1,123
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,010
Cited by
Items 701–800 of 972
Incretin hormone receptors are required for normal beta cell development and function in female mice
Omar, B. A., Ahlkvist, L., Yamada, Y., Seino, Y., & Åhrén, B. (2016) · Peptides · doi:10.1016/j.peptides.2016.03.012 · Cited by 9
Self-citationThe early history of GIP 1969–2000: From enterogastrone to major metabolic hormone
Marks, V. (2019) · Peptides · doi:10.1016/j.peptides.2019.170155 · Cited by 9
Irwin, N., Hunter, K., & Flatt, P. R. (2007) · Peptides · doi:10.1016/j.peptides.2007.08.008 · Cited by 9
Seno, Y., Ikeguchi, E., & Yabe, D. (2025) · Diabetology International · doi:10.1007/s13340-025-00818-w · Cited by 10
“Alongside these incretin receptor agonists, GIP receptor antagonists have garnered significant interest, driven by evidence suggesting that endogenous GIP exacerbates obesity and insulin resistance in high-fat dietary conditions [19].”
Lafferty, R. A., Flatt, P. R., Gault, V. A., & Irwin, N. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0339 · Cited by 8
“As such, it has been demonstrated that GIPR-null mice are protected against high-fat-fed-induced obesity and insulin resistance (Miyawaki et al. 2002), indicating a role for the GIPR in the onset of obesity (Flatt 2008).”
BackgroundThe unexpected role of GIP in transforming obesity treatment
Zandvakili, I., & Pérez–Tilve, D. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.022 · Cited by 9
Alcaino, C., Reimann, F., & Gribble, F. M. (2024) · The Journal of Physiology · doi:10.1113/jp286293 · Cited by 10
“However, the opposing idea that endogenous GIP is pro-adipogenic is supported by findings that mice lacking Gipr are protected against diet induced obesity (Miyawaki et al., 2002) and that humans with loss of function GIPR variants have a lower average body mass index (Kizilkaya et al., 2024).”
Spexin is a biomarker of the process that regulates leptin sensitivity
Ahmed, M. B., Habib, A. M., Badran, S. M., Alsherawi, A., Syed, A., Khoogaly, H., Hammouda, A., Abou‐Samra, A., & Doi, S. A. R. (2025) · Peptides · doi:10.1016/j.peptides.2025.171416 · Cited by 8
Incretin-Based Therapy for Type 2 Diabetes Mellitus: Pancreatic and Extrapancreatic Effects
Hartman, I., Rojas, E., & Rodríguez-Molina, D. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f27d · Cited by 8
“GIP and GLP-1 receptor–knockout mice are resistant to the development of diet-induced insulin resistance and obesity.(40,41) A recent study by Day et al(42) involves a chimeric peptide resulting of the amino acid sequence and structure of both GLP-1 and glucagon and has been proven to be capable of potent, sustained s…”
BackgroundGlucose-dependent insulinotropic polypeptide - a new link in the development of obesity
Shestakova, E. A., Ильин, А. В., Shestakova, M. V., & Dedov, I. I. (2015) · Obesity and metabolism · doi:10.14341/omet2015116-19 · Cited by 8
Nutritional control of thyroid morphogenesis through gastrointestinal hormones
Takagishi, M., Aleogho, B. M., Okumura, M., Ushida, K., Yamada, Y., Seino, Y., Fujimura, S., Nakashima, K., & Shindo, A. (2022) · Current Biology · doi:10.1016/j.cub.2022.01.075 · Cited by 8
Self-citationGlycemic control after metabolic surgery: a Granger causality and graph analysis
Previti, E., Salinari, S., BERTUZZI, A., Capristo, E., Bornstein, S. R., & Mingrone, G. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00042.2017 · Cited by 9
“GIP receptor knockout rodents are protected from obesity-related diabetes (32), and animals genetically engineered to lack K cells also resist development of high fat diet-induced obesity and insulin resistance without any collateral serious adverse effect (1).”
BackgroundShimazu‐Kuwahara, S., Kanemaru, Y., Harada, N., Ikeguchi, E., Ueda, Y., Yamane, S., Murata, Y., Yasoda, A., Kieffer, T. J., & Inagaki, N. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12978 · Cited by 8
Nishiya, Y., Daimon, M., Mizushiri, S., Murakami, H., Tanabe, J., Matsuhashi, Y., Yanagimachi, M., Tokuda, I., Sawada, K., & Ihara, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-71853-7 · Cited by 11
Growth Hormone and Body Composition
Mersebach, H., & Feldt‐Rasmussen, U. (2005) · KARGER eBooks · doi:10.1159/000088423 · Cited by 8
Sekar, R., & Chow, B. (2013) · Hormone and Metabolic Research · doi:10.1055/s-0033-1353155 · Cited by 10
Chen, Z., Fu, X., Kuang, J., Chen, J., Chen, H., Pei, J., & Yang, H. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0133-7 · Cited by 7
“Studies have shown that the secretion of GIP increases significantly after the excessive ingestion of nutrients, indicating that GIP plays an important role in the development of obesity and insulin resistance induced by a high-calorie diet [28].”
BackgroundGaffey, R. H., Takyi, A. K., & Shukla, A. P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377319 · Cited by 8
“Further supporting the evidence of GIP as a so-called ‘obesity hormone,’ GIPR knock-out mice did not gain weight, even on high-fat diets [52].”
Oteng, A., Liu, L., Cui, Y., Gavrilova, O., Lü, H., Chen, M., Weinstein, L. S., Campbell, J. E., Lewis, J. E., Gribble, F. M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci182325 · Cited by 8
“Early work demonstrated that GIP receptor and GIP-KO mice showed reduced body weight gain under different experimental conditions, associated with improvements in glucose homeostasis (14, 15).”
Regulation of feeding and therapeutic application of bioactive peptides
Ueno, H., Zhang, W., & Nakazato, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108187 · Cited by 7
Yang, G., Liang, X., Jiang, Y., Li, C., Zhang, Y., Zhang, X., Chang, X., Shen, Y., & Meng, X. (2022) · Aquaculture Nutrition · doi:10.1155/2022/4330251 · Cited by 7
“Moreover, the diet-induced obesity is alleviated via reducing adipose tissue mass in the mice of GIPR knockout or antag-onism [19, 20].”
Serotonergic regulation of appetite and sodium appetite
Shin, Y., Kim, S., & Sohn, J. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13328 · Cited by 7
“Given the well-known functions of these neuropeptides/hormones have in the control of feeding behavior and energy homeostasis, 8,42 – 50 some of their metabolic effects may in part be mediated by their cognate receptors expressed by the DRN serotonergic neurons.”
The Impact of Gastrointestinal Hormones on Human Adipose Tissue Function
Radziszewska, M., Ostrowska, L., & Smarkusz-Zarzecka, J. (2024) · Nutrients · doi:10.3390/nu16193245 · Cited by 7
“Studies conducted on animal models with diet-induced obesity have shown that these subjects display hyperplasia of K cells and increased GIP production The most significant study demonstrating the role of GIP in the development of obesity was conducted by Miyawaki et al. [62].”
BackgroundDai, J., Sriboonchitta, S., Zi, C., & Yang, Y. (2013) · Advances in intelligent systems and computing · doi:10.1007/978-3-319-03395-2_19 · Cited by 7
“These studies reported various factors that were associated with obesity risk from the perspectives of medicine, biology, genetic, and epidemiology [2] [12] [16] [24] .”
BackgroundSugunan, D., Nair, A. K., Kumar, H., & Gopalakrishnapillai, A. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-118 · Cited by 8
“This suggests that GIP is an obesity promoting factor [21,22].”
BackgroundJensen, S. R., Schoof, E. M., Wheeler, S. E., Hvid, H., Ahnfelt‐Rønne, J., Hansen, B. F., Nishimura, E., Olsen, G. S., Kislinger, T., & Brubaker, P. L. (2017) · Endocrinology · doi:10.1210/en.2017-00194 · Cited by 7
“Mice deficient in either GIP signalling or NT S are thus resistant to diet-induced obesity (54,55).”
BackgroundFuture Drug Treatments for Type 2 Diabetes
Bailey, C. J. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch60 · Cited by 7
GPCR targets in type 2 diabetes
Atanes, P., & Persaud, S. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816228-6.00018-0 · Cited by 11
Antiobesogenic effects of central GIPR antagonism
Yue, J. T. Y., & Lam, T. K. T. (2019) · Journal of Clinical Investigation · doi:10.1172/jci130755 · Cited by 7
“GIP stimulates lipid deposition in visceral adipose tissue and stimulates adipogenesis (9, 21); thus, GIPR antagonism in adipose tissue, for example, may help to improve insulin sensitivity and thereby beneficially affect body weight and satiety.”
BackgroundMechanisms of glucose sensing and multiplicity of glucose sensors
Thorens, B. (2004) · Annales d Endocrinologie · doi:10.1016/s0003-4266(04)95624-7 · Cited by 9
“However, inactivation of this receptor gene protected mice from high fat diet-induced obesity and transfer of this mutation in ob/ob mice reduced their body weight [19].”
BackgroundGastric inhibitory polypeptide links overnutrition to obesity
Ballinger, A. (2003) · Gut · doi:10.1136/gut.52.3.319 · Cited by 7
York, D. A. (2003) · Wiley eBooks · doi:10.1002/0470862092.d0504 · Cited by 7
Ciliary localization of GPR75 promotes fat accumulation in mice
Chávez, M., Asthana, A., & Jackson, P. K. (2024) · Journal of Clinical Investigation · doi:10.1172/jci185059 · Cited by 6
Masuda, K., Aoki, K., Kamiko, K., Takihata, M., Ito, Y., Nagakura, M., Kawasaki, S., Akema, N., Hasegawa, M., Nakajima, S., et al. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.790365 · Cited by 6
“Inhibition of GIP signaling is beneficial for preventing obesity, as previously reported [24].”
ResultKamoi, K., Shinozaki, Y., Furukawa, K., & Sasaki, H. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej11-0245 · Cited by 7
Yang, G., Liang, X., Qin, C., Yang, L., Zhang, Y., Lu, R., Yan, X., Meng, X., & Nie, G. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.737682 · Cited by 6
GIPR gene expression in testis is mouse specific and can impact male mouse fertility
Killion, E. A., Hussien, R., Shkumatov, A. A., Davies, R., Lloyd, D. J., Véniant, M. M., Lebrec, H. N., & Fort, M. M. (2022) · Andrology · doi:10.1111/andr.13166 · Cited by 6
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Bailey, C. J., & Flatt, P. R. (2024) · Peptides · doi:10.1016/j.peptides.2024.171168 · Cited by 6
Roy, S. A. B., Langlois, M., Carrier, J., Boudreau, F., Rivard, N., & Perreault, N. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i14.1579 · Cited by 7
Li, P., Zhu, L., Wang, G., Yang, X., Yi, B., & Zhu, S. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.01.009 · Cited by 6
“[27] Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, et al.”
BackgroundMasuda, A., Seino, Y., Murase, M., Hidaka, S., Shibata, M., Takayanagi, T., Sugimura, Y., Hayashi, Y., & Suzuki, A. (2019) · Nutrients · doi:10.3390/nu11051045 · Cited by 6
Self-citationIncretin Hormones in the Control of Immunometabolism
Fishman, S., Zvibel, I., & Varol, C. (2019) · Immunometabolism · doi:10.20900/immunometab20190004 · Cited by 6
“In further support of this, we have shown that continuous administration of the long-acting GIP analogue [D-Ala2]GIP reduces inflammation in the epiWAT of HFD-fed mice, as manifested by fewer infiltrating innate and adaptive proinflammatory immune cells, attenuated production of pro-inflammatory mediators and improved…”
BackgroundResultInfluentialIslet adaptation in GIP receptor knockout mice
Åhrén, B., Yamada, Y., & Seino, Y. (2019) · Peptides · doi:10.1016/j.peptides.2019.170152 · Cited by 6
Self-citationHarger, A., Stemmer, K., Tschöp, M., & Müller, T. D. (2019) · Der Internist · doi:10.1007/s00108-019-0649-9 · Cited by 7
The GIPR is Predominantly Localized to Non-Adipocyte Cell Types Within White Adipose Tissue
Campbell, J. E., Beaudry, J. L., Svendsen, B., Baggio, L. L., Gordon, A. N., Ussher, J. R., Wong, C. K., Gribble, F. M., D’Alessio, D. A., Reimann, F., et al. (2022) · doi:10.2337/figshare.19184462 · Cited by 6
Metformin Boosts Intestinal Lipid Sensing via GIP to Suppress Feeding
Kuah, R., Wang, M. T., Yang, Z., Back, G., Li, R., Bruce, K., LoChoy, J. N., Beaudry, J. L., Barros, D. R., Zhang, S., et al. (2025) · Diabetes · doi:10.2337/db25-0100 · Cited by 5
Costa, M. P., Sousa, H. S., Oliveira, C. R., Amorim-Cruz, F., Bouça‐Machado, R., Barbosa, E., Carneiro, S., & Sousa‐Pinto, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-72456-2 · Cited by 5
Human Obesity: Its Hormonal Basis and the Role of Gastric Inhibitory Polypeptide
Marks, V. (2006) · Medical Principles and Practice · doi:10.1159/000094265 · Cited by 5
Pivovarova‐Ramich, O., Gögebakan, Ö., Osterhoff, M. A., Nauck, M. A., Pfeiffer, A. F. H., & Rudovich, N. N. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.08.004 · Cited by 6
Diabetic Foot - Recent Advances
Raghav, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102211 · Cited by 5
Romaní‐Pérez, M., Bullich‐Vilarrubias, C., López‐Almela, I., & Sanz, Y. (2023) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300474 · Cited by 5
Effect of gastric bypass combined with ileal transportation on type 2 diabetes mellitus
Gao, Z., Wang, B., Gong, X., Yao, C., Ren, D., Shao, L., Pang, Y., & Liu, J. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.5928 · Cited by 5
“Previous studies have reported that GIP receptor gene knockout reduces the efficacy of GIP and therefore promotes insulin resistance, indicating that GIP may serve an important role in the development of T2DM (35,36).”
Gastrointestinal Hormones and Gut Endocrine Tumors
Vella, A. V., & Drucker, D. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00039-0 · Cited by 6
Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_12 · Cited by 5
“Animal experiments suggest that GIP receptors on adipose tissue are essential for adipocyte triglyceride storage after meal ingestion: GIP receptor knock-out mice do not become obese when fed a high-fat diet [53].”
BackgroundEndoCompass project: research roadmap for diabetes, obesity, and metabolism
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., Beck, J., Chiarelli, F., León, D. D. D., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf065 · Cited by 5
Wu, B., Falsey, J. R., Netirojjanakul, C., Herberich, B., Holder, J. R., Sham, K. K. C., Aral, J., Forsythe, N., Walker, K. W., Lu, S.-C., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00032 · Cited by 4
Innovative approaches to the treatment of obesity: from pharmacotherapy to nanomedicine
Romantsova, T. I. (2024) · Obesity and metabolism · doi:10.14341/omet13184 · Cited by 5
Donado-Pestana, C. M., Vasconcelos, A. D., Mantovam, V. B., de Lima, G. C., Rodrigues, L., Barbeiro, H. V., Fock, R. A., de Souza, H. P., Franco, B. D. G. D. M., & Fiamoncini, J. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.109958 · Cited by 4
Future Drug Treatments for Type 2 Diabetes
Bailey, C. J. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch67 · Cited by 4
Incretins and Regulation of Insulin Secretion
Nauck, M. A., & Meier, J. J. (2008) · Springer eBooks · doi:10.1007/978-4-431-75452-7_17 · Cited by 4
Treatment of Type 2 Diabetes in Patients with Obesity
Guzman, H., Hasan, L. Z., & Reid, T. J. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.10.004 · Cited by 4
Al‐Zaid, B., & Al‐Sabah, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1528295 · Cited by 5
“Studies showing that GIPR-knockout mice were resistant to weight gain when fed a high-fat diet suggested that blocking the actions of GIP may be a viable strategy for treating obesity (Miyawaki et al., 2002).”
Osaki, N., Suzukamo, C., Onizawa, K., Hase, T., & Shimotoyodome, A. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1216-y · Cited by 4
“Moreover, another recent study showed that the GIP/GIPR gene polymorphisms were strongly associated with visceral fat accumulation in the Japanese population [43].”
BackgroundJacobi, S. F., Khajavi, N., Kleinau, G., Teumer, A., Scheerer, P., Homuth, G., Völzke, H., Wiegand, S., Kühnen, P., Krude, H., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13634 · Cited by 7
“On the other hand, several studies suggest that inhibition of GIPR signalling could be beneficial in obesity prevention.(22) Therefore, loss-of-function variants may represent a potential mechanism for positively impacting glucose homeostasis or metabolic diseases on a larger scale.”
BackgroundThe Link between Three Single Nucleotide Variants of the GIPR Gene and Metabolic Health
Michałowska, J., Miller‐Kasprzak, E., Seraszek‐Jaros, A., Mostowska, A., & Bogdański, P. (2022) · Genes · doi:10.3390/genes13091534 · Cited by 4
“The research showed that GIPR knockout mice are prevented from developing obesity induced by a high-fat diet (HFD) [46].”
BackgroundCataldi, S., Aprile, M., Perfetto, C., Angot, B., Cormont, M., Ciccodicola, A., Tanti, J., & Costa, V. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151320 · Cited by 4
Sridhar, A., Khan, D., Flatt, P. R., Moffett, R. C., & Irwin, N. (2023) · Peptides · doi:10.1016/j.peptides.2023.171093 · Cited by 6
Treatment Strategies for Type 2 Diabetes Based on Incretin Action
Gallwitz, B., & Nauck, M. A. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-13 · Cited by 5
New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin
Gagliardino, J. J., Santoro, S., Arellano, S., & Girolamo, G. D. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.9.1495 · Cited by 4
“These mice develop glucose intolerance, decreased insulin secretion and are resistant to the development of obesity when they are fed a fat-rich diet [54] .”
BackgroundGastrointestinal Peptide Hormones Regulating Energy and Glucose Homeostasis
Drucker, D. J. (2006) · Elsevier eBooks · doi:10.1016/b978-012088394-3/50009-x · Cited by 5
Triacylglycerol synthesis and energy metabolism: a gut reaction?
Nelson, D., & Yen, C. E. (2009) · Clinical Lipidology · doi:10.2217/clp.09.67 · Cited by 5
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2024) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2024.09.003 · Cited by 3
Glucose sensing and homeostasis by adipocyte GPCR
Hasan, N., & Chhabra, K. H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1657747 · Cited by 3
A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice
Davies, I., Turland, A., Tran, H. D., Wong, C., Cahn, O., Dunsterville, C., Sun, Y., Xiao, Y., Murphy, K. G., Bloom, S. R., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70300 · Cited by 3
Vignera, S. L., & Condorelli, R. A. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag149 · Cited by 3
“This β -arrestin pathway may mediate the weight loss effects of GIP receptor agonism through hypothalamic circuits, potentially explaining why GIPR variants affecting β -arrestin recruitment disproportionately impact body weight outcomes relative to glycemic effects [49].”
Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism
Lewis, J. E., Montaner, M., Nuzzaci, D., James-Okoro, P.-P., Harada, N., Inagaki, N., Dodson, W. S., Knerr, P. J., Douros, J. D., Gribble, F. M., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01575-z · Cited by 6
“1c–e), mirroring the previously reported phenotypes of germline global Gipr KO mice and Gipr fx/fx mice crossed with Nestin-Cre to drive KO throughout the central nervous system (CNS) 4,9 .”
Kamoi, K., & Sasaki, H. (2014) · Internal Medicine Open Access · doi:10.4172/2165-8048.s6-004 · Cited by 3
“Although the limitation of this study is having no value of p-GIP in control, this study indicated that GIP secretion may have a function of insulin resistance [51] in patients with T2DM as well as a function of obesity [52-56].”
BackgroundÇelik, A., Dixon, J. B., Pouwels, S., Celik, B. O., Karaca, F. C., Gupta, A. K., Santoro, S., & Ugale, S. M. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010245 · Cited by 3
“GIP is a hormone that is obesogenic and insulinotropic, and strategies to block GIP production are beneficial for these patients.(24) 25 In contrast, the distal gut hormones (eg, GLP-1 and PYY) or their agonists, are beneficial for obese and diabetic patients.”
Background2) Diabetes Mellitus Characterized by Impaired Insulin Secretion in Japanese
Inagaki, N. (2016) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.105.396 · Cited by 3
Doubles-agonistes, tri-agonistes et multi-agonistes incrétines/glucagon
Phan, F., & Andréelli, F. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.10.010 · Cited by 3
The Role of Incretins in Insulin Secretion
Schroeder, B. E., & Kolterman, O. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_4 · Cited by 3
Role of the Gut Peptide Glucose-Induced Insulinomimetic Peptide in Energy Balance
Pfeiffer, A. F. H., Rudovich, N. N., Weickert, M. O., & Isken, F. (2010) · Results and problems in cell differentiation · doi:10.1007/978-3-642-14426-4_15 · Cited by 4
“This is highly reminiscent of the observations made in high fat diet–fed mice ( Miyawaki et al. 2002 ) and may be interpreted to indicate that GIP is involved in regulating physical activity upon intake of energy-dense diets.”
BackgroundInfluentialGood, D. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-285-4_71 · Cited by 4
Ablation of Sax2 gene expression prevents diet‐induced obesity
Simon, R., Britsch, S., & Bergemann, A. D. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07960.x · Cited by 4
Control of intestinal stem cell fate: A novel approach to treating diabetes
Yamane, S., & Inagaki, N. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12390 · Cited by 3
Kishimoto, M., & Noda, M. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0260-8 · Cited by 3
“It is well known that GIP promotes the efficient storage of ingested fat and directly links overnutrition to obesity [38–40].”
BackgroundCholecystokinin knockout mice are resistant to high-fat diet-induced obesity
Lo, C., Georgievsky, M., Woods, S. C., & Tso, P. (2011) · Appetite · doi:10.1016/j.appet.2011.05.215 · Cited by 3
Physiology of gut hormones: an overview
Wittert, G., & Chapman, I. M. (2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000200528.76947.7f · Cited by 3
Glucose-dependent insulinotropic polypeptide: its role in glucose and lipid homeostasis
Tseng, C. (2003) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200302000-00009 · Cited by 3
Ortiz-Fraguada, M. Y., & Relling, A. E. (2022) · Translational Animal Science · doi:10.1093/tas/txac089 · Cited by 3
Ørskov, C., Hjorth, S. A., Jensen, A. D., & Vilsbøll, T. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.03.007 · Cited by 3
Nuevas perspectivas en el tratamiento de la obesidad: el aparato digestivo como órgano endocrino
Rodríguez, M. B. S., Gómez-Pan, A., & Casieri, R. C. (2006) · Medicina Clínica · doi:10.1016/s0025-7753(06)72238-2 · Cited by 3
Which is the real nature of glucose‐dependent insulinotropic peptide?: Endogenous vs pharmacological
Yamazaki, Y., & Seino, Y. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14357 · Cited by 3
“The early report demonstrated that GIP receptor knockout (GIPR - / - ) mice is resistant to diet-induced obesity 1 .”
Self-citationSzostak, B., Kułaga, M., Kasprzak, A., Grzybek, M., Mazur-Lesińska, D., Wielgosz-Biała, S., Tyszkiewicz, K., Łozowski, B., Kasprzak, M., & Wilczyńska, B. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.361 · Cited by 3
Besci, Ö., Güler, M. Ç., Foss‐Freitas, M. C., & Oral, E. A. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2574318 · Cited by 3
“Despite conflicting findings from murine studies regarding their role in obesity [126,127], this dual mechanism of tirzepatide has demonstrated significant therapeutic benefits in patients with lipodystrophy syndromes [128].”
Endogenous GIP signaling is indispensable for DPP ‐4 inhibitor‐mediated metabolic control in mice
Kubota‐Okamoto, S., Kubota, S., Tsuchida, H., Liu, Y., Banno, S., Imaizumi, T., Fujisawa, T., Takahashi, Y., Kato, T., Horikawa, Y., et al. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70252 · Cited by 2
“Historically, GIP was considered an obeso-genic hormone due to its lipogenic actions in adipocytes 22,23 .”
Self-citationGIPR signaling modulates PYY-induced hypophagia and malaise in rodents
Borner, T., Pataro, A. M., Curtis, G. R., Alonso, B., Hu, J., Fortin, S. M., Koul‐Tiwari, R., Hughes, E. A. G., Kong, J., Jordan, E., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102334 · Cited by 2
Nicholls, H., Vargas, J. D., Sanghvi, M. M., Ahn, H., Chahal, C. A. A., Khanji, M. Y., Petersen, S. E., Munroe, P. B., & Aung, N. (2026) · Nature Communications · doi:10.1038/s41467-026-69982-0 · Cited by 4
“Notably, GIP (gastric inhibitory polypeptide — known to stimulate insulin and glucagon secretion) hasshown promise as a drug target for obesity 48 , diabetes 51 and HF with preserved ejection fraction 52 .”
InfluentialBeyond GLP‐1: The Cardiometabolic Potential of Dual GLP‐1/GIP Receptor Agonists
Xue, C. (2026) · iNew Medicine · doi:10.1002/inm3.70048 · Cited by 2
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Davies, I., Holst, J. J., ROSENKILDE, M. M., & Tan, T. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-043740 · Cited by 3
Self-citation
Metadata
- Authors
- Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., Hiai, H., Mizunoya, W., Fushiki, T., Holst, J. J., Makino, M., Tashita, A., Kobara, Y., Tsubamoto, Y., Jinnouchi, T., Jomori, T., & Seino, Y.
- Affiliations
- Kyoto University (JP)
- University of Copenhagen (DK)
- Sanwa Kagaku Kenkyusho Co., Ltd. (Japan) (JP)
- Corresponding author
- Seino, Yutaka
- Venue
- Nature Medicine
- Published
- 2002-06-17
- Volume
- 8
- Issue
- 7
- Pages
- 738-742
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2102392334
- Cited by
- 963
- References
- 24
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 64 · 2023: 45 · 2022: 38 · 2021: 39 · 2020: 37 · 2019: 66 · 2018: 39 · 2017: 45 · 2016: 38 · 2015: 42 · 2014: 44 · 2013: 38 · 2012: 38
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, obesity, insulin resistance, high-fat diet, adiposity, respiratory quotient, fat oxidation, anti-obesity drugs, overnutrition
- MeSH terms
- Adipose Tissue, Animals, Body Weight, Crosses, Genetic, Dietary Fats, Gastric Inhibitory Polypeptide, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.